Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.
Also called NCT06215586
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 303 participants
- Registry
-
NCT06215586 -
2023-508737-13
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Belgium, Bulgaria, Canada, Czechia, Germany, Hungary, Italy, Netherlands, New Zealand, Poland, Spain, Taiwan, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT06215586. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-13 (actual); primary completion 2025-09-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)
- Acronym
- Cycle-2-PEF
- Condition
- Heart Failure
- Condition
- Heart Failure Preserved Ejection Fraction
- Condition
- Cardiovascular Diseases
- Condition
- Heart Diseases
- Intervention (Drug)
- Tovinontrine (CRD-750)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct06215586- Content hash
8a80fb213b2edad3aff9e62cd9e7c08fbc1796f43797a1afbab0b5e73865c490